Dr. Koffman’s ASCO 2020 “Top 12” Picks
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held virtually in May. While ASCO remains more focused on the latest research in solid tumors, there were several worthwhile abstracts related to CLL. Dr. Koffman takes us through his “Top 12” abstracts in short videos with accompanying text. Here are numbers 12, 11, and 10.
ASCO 2020 Top 12
#12 The shift in therapies for the treatment of CLL patients in the US Veterans Health Administration
#11 Clinical activity of anti-ROR1 antibody cirmtuzumab in combination with ibrutinib
#10 Initial results of MRD-driven, time-limited therapy with zanubrutinib, obinutuzumab and venetoclax cllsociety.org/2020/06/asco...